Kornimate/medical-research-clean huggingface dataset:
assisted partner services and hivst in western kenya

Conditions: Hiv

Summary: this study includes different designs with aim 1 being a cluster randomized controlled trial to investigate the use of hiv self-testing (hivst) as a mode of hiv testing in western kenya in addition to the standard of care, assisted partner services (aps). aim 2 includes focus group discussions, in-depth interviews, semi-structured interviews, direct observation of facility infrastructure and clinic procedures, and data extraction from facility and county/national databases and expenditure reports to study acceptability, costs, and implementation aspects of hivst within the aps framework.


Eligibility criteria:
inclusion criteria: aim 1: * men and women * tests hiv positive and is not in care or on treatment * ≥18 years old * willing and able to provide informed consent * able to provide locator information for sexual partners aim 2: * ≥18 years old * willing and able to provide informed consent exclusion criteria: aim 1: * pregnancy * reports intimate partner violence during last month * \<18 years old aim 2: • \<18 years old

Keywords: hiv self-testing assisted partner services acceptability implementation science
stockholm acute kidney injury cohort

Conditions: Acute Kidney Injury

Summary: since 2009, adult patients with acute kindney injury (aki) at the department of nephrology, danderyd university hospital and karolinska institutet, have been included in a prospective cohort. all patients were treated and evaluated according to a detailed clinical memorandum, and data collected prospectively. by 2020, 1861 patiens have been included of which 1519 fulfill current aki criteria (as defined by kdigo aki guidelines) and will be evaluated regarding the following main research questions: 1. descriptive study on patient characteristics, changes in biomarkers and in-hospital outcome. 2. one year outcome with focus on renal and cardiovascular outcomes. 3. long-term outcome (up to 10 years) with focus on renal and cardiovascular outcomes.

acure kidney injury (aki) remains a complex clinical challenge associated with high risk for short-term and long-term adverse events. since 2009 patients with aki at the department of nephrology, danderyd university hospital and karolinska institutet, have been included in a prospective cohort. adult patients with either s-creatinine \>130 micromol/l and previously unknown level, or 30% increase from previous known level were included; patients on dialysis were not included. all patients were treated and evaluated according to a detailed clinical memorandum, and data collected prospectively. by 2020, 1861 patiens have been included of which 1519 fulfill current aki criteria and will be evaluated regarding the following main research questions: 1. descriptive study on in-hospital outcome (death, renal recovery), patient characteristics, hyperkalemia and changes in biomarkers reflecting inflammation, acidosis and malnutrition. 2. one year outcome with focus on renal and cardiovascular outcomes (death, new dialysis, worsened renal function, myocardial infarction, stroke, or heart failure; marce). 3. long-term outcome (up to 10 years) with focus on renal and cardiovascular outcomes (marce).

Eligibility criteria:
inclusion criteria (one of the following): * serum creatinine (scr) \>130 µmol/l (1.47 mg/dl) at admission with previously unknown baseline, * increase in scr by 30% from previous stable out-patient value. exclusion criteria: ongoing dialysis treatment.

Keywords: acute renal failure hyperkalemia major adverse cardiovascular event
dexmedetomidine infusion during laparoscopic adrenalectomy

Conditions: Pheochromocytoma

Summary: the investigators planned this study to investigate the effects of dexmedetomidine administration on intraoperative hemodynamic stability in patients with pheochromocytoma.


Eligibility criteria:
inclusion criteria: 1. ages of 20 and 70 2. american society of anesthesiologists(asa) physical status classification i to iii, 3. planned laparoscopic adrenalectomy for pheochromocytoma. exclusion criteria: 1. emergency operation, 2. re-operation, 3. combined surgery with other departments, 4. body mass index (bmi) \>32 kg/m2, 5. history of arrhythmias (especially av nodal block) and ventricular conduction abnormalities, 6. uncontrolled hypertension (diastolic blood pressure \>110mmhg) 7. bradycardia (heart rate \< 40 beats per minute), 8. history of heart failure, hepatic and/or renal failure, 9. history of cerebrovascular disease (cerebral hemorrhage, cerebral ischemia), 10. history of beta-blocker therapy, 10) history of uncontrolled psychiatric disease.
safety and efficacy of juvederm® voluma™ for correction of mid-face volume deficiency

Conditions: Mid-face Volume Deficiency

Summary: this is a prospective, open-label experience study to be conducted at 6 clinical sites in australia, with the objective to collect efficacy and safety information for juvederm® voluma™ when used for volumising the mid-face and cheek area.


Eligibility criteria:
inclusion criteria: * subjects with mild to severe mid-face and cheek volume deficit due to age-related changes, who are likely to improve by at least 2 grades following treatment with the study compound, based on a study-specific scale, as assessed by the study physician exclusion criteria: * subjects who have a pre-existing medical condition or who have received any treatments or procedures which may impact on the assessment of the effects of the study compound. * subjects with a history of allergies or other side effects to dermal fillers, lidocaine, hyaluronic acid or other component of the study compound. * subjects were are pregnant or breast-feeding or who are of child-bearing potential and who are not prepared to practice an adequate form of contraception during the course of the study * subjects with a history of alcoholism or drug abuse or dependence
a study of thymic humoral factor (thf gamma 2) in hiv-infected patients

Conditions: HIV Infections

Summary: to investigate the safety of thymic humoral factor (thf gamma 2), its effect on hiv load based on at least a 75 percent decrease in hiv quantitative pcr rna copies/ml, and its persistence when administered in combination with an antiretroviral nucleoside derivative (zidovudine; azt). to assess the effects of thf gamma 2 on t-cells, quality of life, and progression of disease.

all patients receive 12 weeks of azt before being randomized to self-administer one of two doses of thf gamma 2 or placebo for 15 consecutive days and then twice weekly for an additional 50 weeks.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * azt or another antiretroviral agent (marketed or investigational under a treatment ind). * primary prophylaxis for pneumocystis carinii pneumonia (pcp), toxoplasmosis, and mycobacterium avium-intracellulare (mai) if patient's cd4 count decreases to \< 200 cells/mm3. * other marketed drugs as required. patients must have: * hiv seropositivity and be either asymptomatic or have persistent generalized lymphadenopathy (pgl). * no history of symptoms in category b or c of 1993 case definition, other than oral candidiasis following previous broad-spectrum antibiotic therapy. * mean cd4 of 200-500 cells/mm3. * hiv-1 positive pcr rna. * ability to self-administer study drug by im injection. * ability to tolerate azt at 600 mg daily during first 8 weeks of run-in period (if azt naive) or tolerated azt at \>= 500 mg daily for at least 3 months but no more than 12 months prior to randomization. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * malignancy. * hematuria. * proteinuria \> 1+. concurrent medication: excluded: * non-antiretroviral agents with known or suspected activity against hiv. * investigational new drugs that are not antiretroviral agents distributed under a treatment ind. patients with the following prior conditions are excluded: myositis within the past 6 months. prior medication: excluded: * experimental therapy, including interleukin-2, interferon, erythropoietin, or filgrastim nucleoside within 6 weeks prior to study entry. * prior antiretroviral therapy (azt-naive patients only). prior treatment: excluded within 6 weeks prior to study entry: * blood transfusion or blood products. active alcoholism, drug abuse, or a mental or psychiatric problem sufficient to prevent adequate compliance with study.

Keywords: drug therapy, combination antiviral agents zidovudine thymic humoral factor gamma 2
comparative evaluation of implant planning software

Conditions: Edentulous Jaw; Edentulous Alveolar Ridge; Edentulous Mouth; Partial-edentulism

Summary: artificial intelligence (ai) is increasingly being integrated into dental implant planning, revolutionizing the way clinicians approach treatment. ai-driven software can enhance the accuracy of implant placement by analyzing complex data sets, including bone density, anatomical structures, and patient-specific factors. this technology enables the creation of precise 3d models and surgical guides, facilitating more predictable and personalized treatment outcomes. additionally, ai algorithms can automate tasks such as segmentation, matching digital impressions with cbct scans, and even suggesting optimal implant positions. the integration of ai in implant planning not only improves clinical efficiency but also contributes to better patient outcomes by reducing surgical risks and enhancing the overall success of implant procedures.


Eligibility criteria:
inclusion criteria: * cbct of patient who needs implant rehabilitations exclusion criteria: * patient not suitable for implant rehabilitation

Keywords: artificial intelligence in implantology ai implant planning ai software
evaluate the safety and efficacy of two types of circular column modulated lenses for delaying the progression of myopia

Conditions: Myopia

Summary: clinical trial to evaluate the safety and effectiveness of two kinds of ring band cylindrical lens in delaying the progression of myopia

two-hundered and forty children aged 6-13 will be recruited and allocated to three groups. subjects that were randomized to receive circular cylindrical mirror modulated frame glasses (compact), circular cylindrical mirror modulated frame glasses (strong defocus) or single vision frame glasses, respectively. primary outcome measure ocular axial length and the secondary indicator is spherical equivalent after cycloplegia.

Eligibility criteria:
inclusion criteria: 1. 6-13 years old; 2. ser: -0.75 to -5.00 dioptres (d). astigmatism and anisometropia of 1.50 d or less; 3. monocular best corrected visual acuity (va) of 1.0 or better; 4. acceptance of random group allocation and the masked study design 5. voluntarily participate in the clinical trial and sign the informed consent; exclusion criteria: 1. strabismus. 2. ocular and systemic abnormalities. 3. prior experience of myopia control. 4. only one eye meets the inclusion criteria.
crux biomedical evaluation of the crux inferior vena cava filter 4

Conditions: Pulmonary Embolism

Summary: the purpose of this study is to determine if the crux vena cava filter system is safe and effective in preventing pulmonary embolism.


Eligibility criteria:
inclusion criteria: * patient has a permanent or temporary risk of pulmonary embolism. * patient must provide informed consent at least one of the following conditions - * proven pe * recurrent pe despite adequate * contraindication to anticoagulation * inability to achieve/maintain therapeutic anticoagulation * iliocaval dvt * large, free-floating proximal dvt * massive pe treated with thrombolysis/thrombectomy * chronic pe treated with thrombectomy * protection during thrombolysis for iliocaval dvt * pe with limited cardiopulmonary reserve * poor compliance with anticoagulation medication * high risk of injury worsening on anticoagulation * multi-trauma patient with high risk of pe * surgical patients at high risk of pe * medical condition with high risk of pe patients with a documented vena cava diameter of 17-28mm patient has ivc anatomy suitable for infra-renal placement patient is willing to be available for the appropriate follow up exclusion criteria: * age \<18 years old * patient has any one of the following conditions: * renal vein thrombosis * ivc thrombosis extending to the renal veins * duplicate ivc * gonadal vein thrombosis * requires supra-renal placement * vena cava diameter of 17-28mm * uncontrolled infectious disease * risk of aseptic pe * uncontrolled coagulopathy * existing inferior vena cava filter implant * life expectancy less than 6 months * pregnant or planning a pregnancy in the next 6 months * condition that inhibits radiographic visualization of the ivc * known allergy or intolerance to polytetrafluoroethylene (ptfe) or nitinol * known hypersensitivity to contract which cannot be pretreated * access vessels preclude same insertion of delivery system * participation in another drug or device trial * unable or unwilling to cooperate with study procedures or required follow-up visits

Keywords: vena cava vena cava filter pulmonary embolism venous thromboembolism risk of pulmonary embolism
collaborative connected health (cch) for pcori

Conditions: Psoriasis

Summary: the investigators propose to evaluate whether an innovative collaborative connected health (cch) model increases access to specialists and improves patient outcomes. cch offers multiple modalities for patients and primary care providers (pcps) to access dermatologists online directly and asynchronously to maximize effectiveness in a real-world setting. cch also fosters team care and patient engagement through active sharing of management plans and multidirectional, informed communication among patients, pcps, and dermatologists. the specific aims of the proposal are to (1) determine whether the cch model results in equivalent improvements in psoriasis disease severity compared to in-person care, (2) determine whether the cch model results in equivalent improvements in quality of life and mental health compared to in-person care, and (3) assess whether the cch model provides better access to care than in-person care.

the investigators propose to conduct a 12-month, pragmatic, randomized controlled trial to evaluate the impact of a collaborative connected health model for psoriasis management compared to inperson care. the pragmatic trial will compare psoriasis severity, quality-of-life, mental health, and access-to-care between the two models. we will enroll 300 psoriasis patients from colorado and california. in addition to recruiting patients from the general population, we will place a specific emphasis on recruiting psoriasis patients living in rural and underserved communities. we will also recruit from the full disease spectrum of mild, moderate, and severe psoriasis patients. we will use an intention-to-treat approach to analyze outcomes and perform longitudinal data analysis using repeated measures approach to identify potential differences in the trend over time between the two arms. to evaluate the utility of cch for increasing access from patients' and clinicians' perspective, the study team will conduct key informant interviews and use qualitative analytical techniques with investigator triangulation and member checking to enhance the validity of the conclusions.

Eligibility criteria:
inclusion criteria: * be age 18 years and older * have physician-diagnosed plaque psoriasis * have access to internet and a digital camera or a mobile phone with camera features * have a primary care provider or the ability to establish primary care exclusion criteria: -

Keywords: pragmatic equivalency teledermatology
allogeneic mesenchymal stem cells for the critical limb ischemia therapy

Conditions: Critical Limb Ischemia

Summary: the clinical trial aims to study the safety and efficacy of adult allogeneic mesenchymal stem cells for the treatment of critical limb ischemia.


Eligibility criteria:
inclusion criteria: 1. males or females in the age group of 18-80 yrs of caucasian origin. 2. peripheral artery disease (pad) against the background of atherosclerosis and diabetes mellitus (dm) 3. critical lower limb ischemia (stages 3-4 by fontaine-pokrovsky or stages 4-6 by rutherford) 4. patients with remaining symptoms of critical limb ischemia (cli) in spite of the performed surgical (endovascular or open) treatment and continuing conservative therapy 5. patients with absent emergency indications to major amputation 6. patients planned for the reconstructive surgery with a questionable remote outcome due to compromised blood outflow 7. ankle brachial pressure index (abpi) ≤ 0.5 or ankle pressure ≤ 70 mm hg 8. patients, if having associated type ii diabetes, should be on medication and well controlled (hba1c ≤ 8.5 %) 9. on regular medication for hypertension if needed 10. normal liver and renal function (or having clinically insignificant deviations, according to the treating physician's opinion) 11. patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits exclusion criteria: 1. humid gangrene or acute/chronic infection of lower limb. 2. dry gangrene with extensive foot lesion (\> 1\\2). 3. acute arterial failure. 4. life-threatening conditions and predicted life expectancy of \< 6 months. 5. presence of neoplasm or bone marrow disease 6. signs of active or chronic, including latent, haemorrhage 7. any acute or chronic infectious disease 8. renal failure determined as twofold or higher elevation of serum creatinine as compared to the upper normal limit 9. hepatic failure determined as the bilirubin, alanine aminotransferase (alt) or aspartate aminotransferase (ast) levels elevated by two and more times over the upper normal limits 10. thrombocytopenia (platelet counts \< 50,000 /µl), leukocytopenia (wbc \< 4,000/µl), immunosuppressive therapy 11. pronounced neurological deficit 12. patients with gait disturbance for reasons other than cli 13. patients not suitable for cell therapy, by the treating physician's opinion 14. cli patients requiring amputation at the proximal to the trans-metatarsal level 15. patients with type i diabetes 16. patients having respiratory complications/left ventricular ejection fraction \< 25% 17. stroke or myocardial infarction within last 3 months 18. patients who are contraindicated for x-ray angiography 19. history of severe alcohol or drug abuse within 3 months of screening 20. pregnant and lactating women. 21. patients tested positive for hiv 1, hepatitis c virus (hcv), hepatitis b virus (hbv) 22. unsigned informed consent
safety and efficacy study in patients with local advanced larynx/hypolarynx carcinoma treated with tpf induction chemotherapy followed by hyperfractionated radiotherapy with cetuximab

Conditions: Laryngeal Neoplasms

Summary: to evaluate the progression free time in patients with completed or partial response \> 30% evaluated over primary tumour (damage t and n) after induction tpf (docetaxel, cisplatin, 5-fu) treated with rt + cetuximab over 2 years.


Eligibility criteria:
inclusion criteria: * patient informed consent must be signed before to start the study. * age between 18 to 70 years. * performance status 0-1 according to ecog scale at the moment of inclusion. * life expectancy \>3 months. * confirmed anatomopathologic diagnosis of local advance scaly larynx or hypolarynx carcinoma iii or iv stage without evidence of distance metastasis, which surgery involve a total laryngectomy. * t3, t4a, t4b or t2 not candidate to a partial laryngectomy. in case of t2 of both locations it will be required iii or iva stage. * patients in medical conditions to receive neoadjuvant treatment with tpf followed by hyperfractionated radiotherapy combined with cetuximab. * presence of a injury measurable with recist criteria. * neutrophils \> or = 1500/mm3, platelets \> or = 150.000/mm3 and haemoglobin \> or =10 g/dl. * renal function appropriate * hepatic function appropriate * serum calcium tight to albumine \< or = 1,25 x upper normal limit (unl). * nutritional status appropriate: weight loss \ or = 35 g/l. * women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. exclusion criteria: * metastatic disease. * surgical treatment, radiotherapy and/or previous chemotherapy. * another tumour locations in head and neck area different from larynx or hypo larynx. * another stages different from iii or iva without distant metastasis and resectable disease. * another previous scaly carcinoma * diagnosis of another neoplasia in last 5 years, except cervix carcinoma in situ and/or basocellular cutaneous carcinoma adequately treated. * active infection treated by atb iv, including active tuberculosis and vih. * hypertension not controled defined as systolic \> or = 180 mm hg and/or diastolic \> or =130 mm hg at rest. * pregnant/lactating women. * systemic immune treatment, chronic and concomitant, or cancer hormone treatment. * another antineoplastics concomitant treatments. * coronary artery disease or history of heart attack in the last 12 months or high risk of arrythmia uncontrolled or cardiac insufficiency uncontrolled. * epoc that required more than 3 hospitalizations in the last 12 months. * active ulcus not controled. * psychiatric illness/social situations that would limit compliance with study requirements * drug abuse (except alcohol abuse) * knowledge of allergic to study treatment. * previous treatment with monoclonal antibodies. * any experimental treatment in the previous 30 days to start the study.
evaluation of effects on skin quality of a centella asiatica extracellular vesicle-based skin care formulation.

Conditions: Skin Quality; Skin Wrinkles; Melanin Hyperpigmentation; Skin Hydration; Skin Elasticity; Skin Redness

Summary: the study evaluates the effects of a skin care formulation containing centella asiatica extracellular vesicles as the main active ingredient on facial appearance and skin quality in healthy participants.

twenty healthy participants will be enrolled and will first undergo a 24-hour skin patch test on the forearm to assess potential irritation or allergic reactions to the test product. after screening, participants were asked to use the test product twice daily (morning and evening) after cleansing their face without using exfoliating products for 28 consecutive days. each application involved 2 drops, evenly applied to the face using fingertips for absorption. product usage was self-recorded, and the products were stored at room temperature. the skin quality tests were conducted at the investigation site hungkuang university onsite by the principal investigator. each participant was to allocate 1 hour per test (including cleansing and waiting time). skin quality tests were performed as a baseline test on day 0 (before using the test product), and subsequent tests at 7, 14, 21, and 28 days after test product use. measured parameters during assessment will include skin hydration, melanin content, skin elasticity, wrinkle percentage, redness area percentage, and pore percentage.

Eligibility criteria:
inclusion criteria: * healthy adults of any gender from the age of 18 to 60 years (inclusive). * absence of chronic diseases, major illnesses, or allergies. exclusion criteria: * currently using any medications or other skincare products

Keywords: centella asiatica extracellular vesicles antioxidants cosmetics skin care anti-inflammatory skin whitening uv damage photoaging skin quality gotu kola